Clinical Trial

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

Study acronym: ALMOND
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy (PMN) who are on optimal supportive care.
Protocol Amendment History 49 amendments
This ClinicalTrials.gov record has been amended 49 times since 2023-01-23; most recent amendment 2026-07-22.
Status change: Recruiting → Active, Not Recruiting 2025-11-06
Status change: Not Yet Recruiting → Recruiting 2023-05-30
Trial Details
NCT Number NCT05707377
Lead Sponsor BeOne Medicines
Conditions Primary Membranous Nephropathy
Enrollment 178 participants
Start Date 2023-04-17
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-23